Login to Your Account



First Target Potentially Worth C$33M

Medicago, Mitsubishi Tanabe Collaborate on VLP Vaccines

By Marie Powers
Staff Writer

Wednesday, March 7, 2012
Canadian biopharma Medicago Inc. clinched a strategic alliance with Japan's Mitsubishi Tanabe Pharma Corp. (MTPC) by executing a master research collaboration agreement to develop and commercialize at least three vaccines using its virus-like particle (VLP) technology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription